PACIRA BIOSCIENCES INC (PCRX)
US6951271005 - Common Stock
PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While PCRX has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on PCRX. These ratings could make PCRX a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
Of the past 5 years PCRX 4 years were profitable.
In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -5.37%, PCRX is in the better half of the industry, outperforming 76.96% of the companies in the same industry.
PCRX's Return On Equity of -10.91% is fine compared to the rest of the industry. PCRX outperforms 76.44% of its industry peers.
With an excellent Return On Invested Capital value of 6.55%, PCRX belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 43.18%.
The last Return On Invested Capital (6.55%) for PCRX is above the 3 year average (4.32%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.37% | ||
| ROE | -10.91% | ||
| ROIC | 6.55% |
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
1.3 Margins
In the last couple of years the Profit Margin of PCRX has declined.
The Operating Margin of PCRX (13.59%) is better than 84.82% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 73.82%, PCRX belongs to the top of the industry, outperforming 80.63% of the companies in the same industry.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.59% | ||
| PM (TTM) | N/A | ||
| GM | 73.82% |
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
PCRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
The debt/assets ratio for PCRX has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.60, we must say that PCRX is in the distress zone and has some risk of bankruptcy.
PCRX's Altman-Z score of 1.60 is fine compared to the rest of the industry. PCRX outperforms 65.97% of its industry peers.
PCRX has a debt to FCF ratio of 3.04. This is a good value and a sign of high solvency as PCRX would need 3.04 years to pay back of all of its debts.
The Debt to FCF ratio of PCRX (3.04) is better than 91.62% of its industry peers.
PCRX has a Debt/Equity ratio of 0.51. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
The Debt to Equity ratio of PCRX (0.51) is worse than 65.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | 3.04 | ||
| Altman-Z | 1.6 |
ROIC/WACC0.79
WACC8.34%
2.3 Liquidity
A Current Ratio of 2.25 indicates that PCRX has no problem at all paying its short term obligations.
PCRX's Current ratio of 2.25 is in line compared to the rest of the industry. PCRX outperforms 43.46% of its industry peers.
A Quick Ratio of 1.89 indicates that PCRX should not have too much problems paying its short term obligations.
PCRX has a Quick ratio (1.89) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.72% over the past year.
The Earnings Per Share has been growing by 22.93% on average over the past years. This is a very strong growth
Looking at the last year, PCRX shows a very strong growth in Revenue. The Revenue has grown by 29.50%.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.88% yearly.
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%9.72%
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%2.83%
3.2 Future
The Earnings Per Share is expected to grow by 8.83% on average over the next years. This is quite good.
Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 0.74% on average per year.
EPS Next Y8.09%
EPS Next 2Y4.99%
EPS Next 3Y9.47%
EPS Next 5Y8.83%
Revenue Next Year2.65%
Revenue Next 2Y0.28%
Revenue Next 3Y5.37%
Revenue Next 5Y0.74%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.95, the valuation of PCRX can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 95.81% of the companies listed in the same industry.
PCRX is valuated cheaply when we compare the Price/Earnings ratio to 27.73, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 5.90, the valuation of PCRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 94.76% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (22.83), we can say PCRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.95 | ||
| Fwd PE | 5.9 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 96.34% of the companies are valued more expensively.
97.38% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.53 | ||
| EV/EBITDA | 4.15 |
4.3 Compensation for Growth
PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)0.74
PEG (5Y)0.26
EPS Next 2Y4.99%
EPS Next 3Y9.47%
5. Dividend
5.1 Amount
No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACIRA BIOSCIENCES INC
NASDAQ:PCRX (12/20/2024, 8:00:00 PM)
After market: 18.98 0 (0%)18.98
-0.59 (-3.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.83%
Inst Owner Change-0.56%
Ins Owners1.05%
Ins Owner Change6.76%
Market Cap876.31M
Analysts72
Price Target19.53 (2.9%)
Short Float %10.63%
Short Ratio7.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.37%
Min EPS beat(2)9.93%
Max EPS beat(2)24.81%
EPS beat(4)2
Avg EPS beat(4)7.73%
Min EPS beat(4)-2.59%
Max EPS beat(4)24.81%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)4
Avg EPS beat(12)-6.49%
EPS beat(16)7
Avg EPS beat(16)-5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-2.6%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.05%
Min Revenue beat(4)-2.6%
Max Revenue beat(4)1.18%
Revenue beat(8)1
Avg Revenue beat(8)-2.41%
Revenue beat(12)1
Avg Revenue beat(12)-2.3%
Revenue beat(16)2
Avg Revenue beat(16)-2.21%
PT rev (1m)-2.9%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.95%
EPS NY rev (1m)2.44%
EPS NY rev (3m)1.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.64%
Revenue NY rev (1m)0.33%
Revenue NY rev (3m)0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.95 | ||
| Fwd PE | 5.9 | ||
| P/S | 1.02 | ||
| P/FCF | 4.53 | ||
| P/OCF | 4.3 | ||
| P/B | 1.17 | ||
| P/tB | 2.83 | ||
| EV/EBITDA | 4.15 |
EPS(TTM)3.19
EY16.81%
EPS(NY)3.22
Fwd EY16.96%
FCF(TTM)4.19
FCFY22.08%
OCF(TTM)4.41
OCFY23.26%
SpS18.67
BVpS16.24
TBVpS6.7
PEG (NY)0.74
PEG (5Y)0.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.37% | ||
| ROE | -10.91% | ||
| ROCE | 9.64% | ||
| ROIC | 6.55% | ||
| ROICexc | 10.46% | ||
| ROICexgc | 24.8% | ||
| OM | 13.59% | ||
| PM (TTM) | N/A | ||
| GM | 73.82% | ||
| FCFM | 22.45% |
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
ROICexc(3y)6.29%
ROICexc(5y)6.55%
ROICexgc(3y)29.94%
ROICexgc(5y)22.81%
ROCE(3y)6.36%
ROCE(5y)5.99%
ROICexcg growth 3Y-7.41%
ROICexcg growth 5Y10.67%
ROICexc growth 3Y-15.58%
ROICexc growth 5Y0.45%
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | 3.04 | ||
| Debt/EBITDA | 2 | ||
| Cap/Depr | 13.52% | ||
| Cap/Sales | 1.19% | ||
| Interest Coverage | 9.06 | ||
| Cash Conversion | 105.52% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.6 |
F-Score6
WACC8.34%
ROIC/WACC0.79
Cap/Depr(3y)71.34%
Cap/Depr(5y)91.2%
Cap/Sales(3y)5.08%
Cap/Sales(5y)5.29%
Profit Quality(3y)415.67%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%9.72%
EPS Next Y8.09%
EPS Next 2Y4.99%
EPS Next 3Y9.47%
EPS Next 5Y8.83%
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%2.83%
Revenue Next Year2.65%
Revenue Next 2Y0.28%
Revenue Next 3Y5.37%
Revenue Next 5Y0.74%
EBIT growth 1Y73.26%
EBIT growth 3Y13.01%
EBIT growth 5Y37.92%
EBIT Next Year23.8%
EBIT Next 3Y17.82%
EBIT Next 5Y12.49%
FCF growth 1Y108.99%
FCF growth 3Y52.67%
FCF growth 5Y32.31%
OCF growth 1Y61.24%
OCF growth 3Y26.17%
OCF growth 5Y25.89%